AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05315102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Care
Description: A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
Study NCT05315102 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical therapy intervention
Description: The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Cerebral Palsy children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
Study NCT05315102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Description: The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Cerebral Palsy children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
Study NCT06408558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypobaric
Description: The effects of ambient pressure changes on glucose metabolism will be studied
Study NCT06408558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground level
Description: The effects of ambient pressure changes on glucose metabolism will be studied
Study NCT06247813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inflammation Support Formula
Description: Turmeric Extract (400mg), Bioperine (Black pepper, 10mg), Ashwagandha (500mg), and Olive Leaf Extract (250mg).
Study NCT06247813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nerve Health Formula
Description: Hydroxocobalamin (Vitamin B12, 1000mcg), Pyridoxal-5-Phosphate (Vitamin B6, 50mg), LMethylfolate (400mcg) and Trimethyl Glycine (Betaine, 750mg).
Study NCT06247813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Redox Support Formula
Description: N-Acetyl-L-Cysteine (500mg), CoQ10 (250mg), Acetyl-L-Carnitine (200mg), Alpha Lipoic Acid (200mg), Benfotiamine (300mg), Selenium (250mcg), Riboflavin (50mg), Zinc (15mg) and Copper (1.8mg).
Study NCT06068309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CareAide App Usage
Description: The study participant uses the CareAide app in addition to prescribed usual therapeutic care
Study NCT06582446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT) - Goserelin
Description: The patients under ADT and the patients who will receive the ADT during the study will be included in the trial.~* ADT will be applied for 24 months in total~* ADT must be given concurrently and adjuvant
Study NCT06582446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose-Rate Interstitial Brachytherapy (HDR BRT)
Description: HDR BRT Procedure will be performed using transperineal catheter implantation under transrectal US-guidance performed under anesthesia, spinal or general with patient in high lithotomy position.)
Study NCT06582446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: EBRT prostate + elective pelvis (Ultra-hypofractionated): 25 Gy in 5 Gy per fraction
Study NCT05307211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Interlaminar Epidural Steroid Injection
Description: Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 ccs 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the restroom after the procedure and followed up for any complications.
Study NCT05307211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Interlaminar Epidural Steroid Injection
Description: Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 ccs 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the restroom after the procedure and followed up for any complications.
Study NCT05404139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Second-generation androgen pathway inhibitor (ARAT), oral tablet
Study NCT05404139 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care SBRT and ADT
Description: Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
Study NCT05404139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care SBRT and ADT
Description: Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
Study NCT05874674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nafamostat Mesylate
Description: Comparison effect of nafamostat and cnoxan
Study NCT05799287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Subcutaneous injection
Study NCT05799287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Telitacicept
Study NCT05131204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered per protocol
Study NCT05131204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Administered per protocol
Study NCT05131204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered per protocol
Study NCT05131204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Administered per protocol
Study NCT05993806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04RD1
Description: 1 tablet of L04RD1
Study NCT05993806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04TD3
Description: 1 tablet of L04TD3
Study NCT05307211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Stabilization Exercises
Description: The physiotherapist will design an exercise protocol for neck stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
Study NCT05307211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck and Scapular Stabilization Exercises
Description: The physiotherapist will design an exercise protocol for neck and scapular stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
Study NCT06091475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other
Description: Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
Study NCT05699408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS068 injection
Description: INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study NCT05699408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study NCT06247917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Busulfan and Melphalan
Description: Use Fludarabine, Busulfan and Melphalan as myeloablative conditioning regimen for untreated MDS-EB patients.
Study NCT05238675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583
Study NCT05238675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05720182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compremium Compressibility Measurement
Description: CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~* Place the probe on the target area~* Identify correct landmark~* Compress the compartment~* Increase steadily the pressure applied by the CP probe to 80 mmHg.
Study NCT05720182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treadmill Running
Description: Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg.
Study NCT05720182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements.
Study NCT03988400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Augmentation
Description: Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
Study NCT03988400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random Vibration
Description: Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
Study NCT05139680 — intervention group
Intervention type: DRUG
Intervention: tafamidis
Description: 80 or 61 milligrams (mg)
Study NCT06510660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab
Description: The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
Study NCT05141383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling
Description: A blood sample and a urine sample after prostate massage will be carried out at baseline
Study NCT06512064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE testing to estimate lung function and aid in disease diagnosis
Study NCT06184633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3.2 MG/ML
Description: Intervention arm receives semaglutide in addition to combined lifestyle intervention
Study NCT06184633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm receives placebo in addition to combined lifestyle intervention
Study NCT05407441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: oral, twice daily, dosage per protocol
Study NCT05407441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV, dosage and schedule per protocol
Study NCT05407441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV, dosage and schedule per protocol
Study NCT04768504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: Tofacitinib 10 mg PO BID for 30 days
Study NCT03955198 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy + durvalumab
Description: Radiotherapy will be administered in combination with Durvalumab
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: VEGF antibody
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: chemotherapy
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: chemotherapy
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: chemotherapy
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Folinate
Description: chemotherapy
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: chemotherapy
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: chemotherapy
Study NCT06493760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: chemotherapy
Study NCT05537753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encore PFO closure device
Description: The Encore PFO closure device comprises an implant component and a single-use delivery system.
Study NCT05537753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA-approved PFO closure device
Description: Chosen by the investigator
Study NCT06220721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine ER
Description: Initiation of nifedipine ER postpartum at SBP ≥140 mmHg or DBP ≥90 mmHg and maintaining BP \<140/90 mmHg during the first 6 weeks postpartum.
Study NCT06220721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine ER
Description: Initiation of nifedipine ER postpartum at SBP ≥140 mmHg or DBP ≥90 mmHg and maintaining BP \<140/90 mmHg during the first 6 weeks postpartum.
Study NCT04991649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-based Asthma Management Training Program
Description: In addition to the routine pediatric asthma outpatient service as received with the TAU group, participants in the ACT group will additionally receive a two-weekly 2-hour Positive Parenting Program (Triple-P) and a four-weekly 2-hour ACT program (a total of six weekly sessions, 6-8 parents per group). The Triple-P aims to increase parental self-regulation and positive parenting practices to promote child cooperation, lead to consistent discipline and promote routines in childhood asthma management. On the other hand, The ACT sessions foster parents' psychological flexibility to cultivate non-judgmental acceptance of difficult parenting experiences, be mindful in daily parenting, develop an observer-self, and promote commitment to one's values.
Study NCT04991649 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual Group
Description: Participants in the treatment-as-usual (TAU) group will receive routine pediatric asthma outpatient services. These services include regular follow-up appointments once every 3-6 months for reviewing the child's health conditions by pediatricians, refilling medications and asthma education (1.5-2 hours every 3-4 weeks) by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare services by psychiatrist/medical social worker for parental training in ADHD care.
Study NCT05954858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
Description: Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
Study NCT04843566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal MRI-guided prostate biopsy
Description: Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
Study NCT04843566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal MRI-guided prostate biopsy
Description: Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
Study NCT04843566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (prophylaxis)
Description: For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy.
Study NCT05906953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG004
Description: Low dose Medium dose High dose
Study NCT04664517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible intramedullary nail (FIN)
Description: Both bone FIN
Study NCT04664517 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexible intramedullary nail (FIN)
Description: Both bone FIN
Study NCT04664517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction auder general anesthesia and long arm cast
Description: Reduction and cast
Study NCT04664517 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reduction auder general anesthesia and long arm cast
Description: Reduction and cast
Study NCT06431048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure.
Description: Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure (tracheostomy + PEG or PEG only).
Study NCT06431048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.
Description: Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure (tracheostomy + PEG or PEG only).
Study NCT05773937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
Study NCT05153746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D colonoscopy
Description: 3D colonoscopy is a new device to enhance endoscopic imaging.
Study NCT05153746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D colonoscopy
Description: 3D colonoscopy is a new device to enhance endoscopic imaging.
Study NCT05159830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral oil
Description: The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Oral oil contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed oral oil.
Study NCT05159830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral oil
Description: Placebo of similar cannabidiol galenic form